Leopold Bertea was appointed in September, 2015 as Executive Vice President of LFB Biotechnologies, head of the new Global Bioproduction division. He is currently responsible for all non-plasma Bioproduction activities at Group level with the goal to manufacture LFB products in the time, quantity and quality required for development and commercialization. Dr. Bertea brings an impressive track record in Biopharmaceutical production, first with Novartis in charge of commercial monoclonal antibody production including Xolair and Ilaris and more recently with Sanofi where he built up and led the first integrated Biologics CMC Platform. Dr. Bertea then covered roles as Vice President Bio-business & Governance for Sanofi’s Global Biotherapeutics in charge of the company’s biologics pipeline including collaboration projects with Regeneron and other partners. He was also a member of the Sanofi global R&D Leading team and a senior Biologics Expert. Dr. Bertea holds a Ph.D. in Chemical Engineering from ETH Zürich.
Executive Vice President, LFB Biotechnologies